These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 34324082)

  • 21. Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study.
    Kobayakawa T; Suzuki T; Nakano M; Saito M; Miyazaki A; Takahashi J; Nakamura Y
    Bone Rep; 2021 Jun; 14():101068. PubMed ID: 33981812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Romosozumab for the treatment of osteoporosis.
    Bandeira L; Lewiecki EM; Bilezikian JP
    Expert Opin Biol Ther; 2017 Feb; 17(2):255-263. PubMed ID: 28064540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonresponder Considerations for Romosozumab Treatment.
    Tominaga A; Wada K; Okazaki K; Nishi H; Terayama Y; Shimamoto S; Kodama Y; Kato Y
    Calcif Tissue Int; 2023 Aug; 113(2):157-165. PubMed ID: 37138124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Denosumab versus romosozumab for postmenopausal osteoporosis treatment.
    Kobayakawa T; Miyazaki A; Saito M; Suzuki T; Takahashi J; Nakamura Y
    Sci Rep; 2021 Jun; 11(1):11801. PubMed ID: 34083636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Romosozumab successfully regulated progressive osteoporosis in a patient with autosomal dominant polycystic kidney disease undergoing hemodialysis.
    Suzuki T; Mizobuchi M; Yoshida S; Terado N; Aoki S; Sato N; Honda H
    Osteoporos Int; 2022 Dec; 33(12):2649-2652. PubMed ID: 35980440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study.
    Lau EMC; Dinavahi R; Woo YC; Wu CH; Guan J; Maddox J; Tolman C; Yang W; Shin CS
    Osteoporos Int; 2020 Apr; 31(4):677-685. PubMed ID: 32047951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of romosozumab for osteoporosis in a patient with osteogenesis imperfecta: A case report.
    Uehara M; Nakamura Y; Nakano M; Miyazaki A; Suzuki T; Takahashi J
    Mod Rheumatol Case Rep; 2022 Jan; 6(1):128-133. PubMed ID: 34491363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    Saag KG; Petersen J; Brandi ML; Karaplis AC; Lorentzon M; Thomas T; Maddox J; Fan M; Meisner PD; Grauer A
    N Engl J Med; 2017 Oct; 377(15):1417-1427. PubMed ID: 28892457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interrelationships between sarcopenia, bone turnover markers and low bone mineral density in patients on hemodialysis.
    Wang Y; Ma W; Pu J; Chen F
    Ren Fail; 2023 Dec; 45(1):2200846. PubMed ID: 37122165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan.
    Hagino H; Tanaka K; Silverman S; McClung M; Gandra SR; Charokopou M; Adachi K; Johnson B; Stollenwerk B
    Osteoporos Int; 2021 Oct; 32(10):2011-2021. PubMed ID: 33772328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis.
    Ebina K; Hirao M; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Okamura G; Etani Y; Takami K; Goshima A; Nakata K
    Bone; 2020 Nov; 140():115574. PubMed ID: 32777516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Romosozumab in postmenopausal women with low bone mineral density.
    McClung MR; Grauer A; Boonen S; Bolognese MA; Brown JP; Diez-Perez A; Langdahl BL; Reginster JY; Zanchetta JR; Wasserman SM; Katz L; Maddox J; Yang YC; Libanati C; Bone HG
    N Engl J Med; 2014 Jan; 370(5):412-20. PubMed ID: 24382002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis.
    Kaveh S; Hosseinifard H; Ghadimi N; Vojdanian M; Aryankhesal A
    Clin Rheumatol; 2020 Nov; 39(11):3261-3276. PubMed ID: 32385757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Romosozumab : a new treatment for severe osteoporosis].
    Uebelhart B; Ferrari S
    Rev Med Suisse; 2021 Apr; 17(735):784-787. PubMed ID: 33881241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab.
    McClung MR; Bolognese MA; Brown JP; Reginster JY; Langdahl BL; Maddox J; Shi Y; Rojeski M; Meisner PD; Grauer A
    Osteoporos Int; 2020 Nov; 31(11):2231-2241. PubMed ID: 32623487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.
    Lewiecki EM; Dinavahi RV; Lazaretti-Castro M; Ebeling PR; Adachi JD; Miyauchi A; Gielen E; Milmont CE; Libanati C; Grauer A
    J Bone Miner Res; 2019 Mar; 34(3):419-428. PubMed ID: 30508316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis.
    Ebina K; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Hirao M; Okamura G; Etani Y; Takami K; Goshima A; Miura T; Nakata K; Okada S
    Joint Bone Spine; 2021 Oct; 88(5):105219. PubMed ID: 34020048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk.
    Lim SY
    Womens Health (Lond); 2022; 18():17455057221125577. PubMed ID: 36154750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
    Mori Y; Kasai H; Ose A; Serada M; Ishiguro M; Shiraki M; Tanigawara Y
    Osteoporos Int; 2018 May; 29(5):1155-1163. PubMed ID: 29423715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland.
    Everts-Graber J; Wenger M; Oser S; Studer U; Steiner C; Ziswiler HR; Sromek K; Schmid G; Gahl B; Häuselmann H; Reichenbach S; Lehmann T
    Osteoporos Int; 2024 Jun; ():. PubMed ID: 38922397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.